CSL Ltd
Company Profile
Business description
CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world’s second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
Contact
655 Elizabeth Street
MelbourneVIC3000
AUST: +61 393891911
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
29,904
Stocks News & Analysis
stocks
Going into earnings, is Netflix stock a buy, a sell, or fairly valued?
stocks
Bapcor is paying for the sins of its past
stocks
Overvalued ASX share as market underestimates downside risks
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,324.60 | 40.80 | 0.44% |
CAC 40 | 8,206.07 | 31.87 | 0.39% |
DAX 40 | 24,258.80 | 427.81 | 1.80% |
Dow JONES (US) | 46,706.58 | 515.97 | 1.12% |
FTSE 100 | 9,403.57 | 49.00 | 0.52% |
HKSE | 25,858.83 | 611.73 | 2.42% |
NASDAQ | 22,990.54 | 310.57 | 1.37% |
Nikkei 225 | 49,185.50 | 1,603.35 | 3.37% |
NZX 50 Index | 13,344.96 | 55.75 | 0.42% |
S&P 500 | 6,735.13 | 71.12 | 1.07% |
S&P/ASX 200 | 9,031.90 | 43.70 | 0.49% |
SSE Composite Index | 3,863.89 | 24.14 | 0.63% |